Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Holding GMAB?
Track your performance easily
Earnings Data
Report Date
Feb 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.36Last Year’s EPS
0.14Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2018
|% Change Since: -12.75%
|Next Earnings Date:Aug 08, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted Genmab's strong financial performance, successful product launches, and strategic advancements in its late-stage pipeline. However, this was tempered by the termination of several early-stage programs and challenges in strategic prioritization. Overall, the company demonstrated resilience and growth potential despite facing some obstacles.Company Guidance
During the Genmab Financial Results Conference Call for the first nine months of 2024, a range of performance metrics and strategic priorities were discussed. Notably, EPKINLY, a key product, reported a 17% quarterly growth, achieving $82 million in global net sales and $203 million year-to-date sales. The company's recurring revenues increased by 37%, primarily driven by royalties from DARZALEX and Kesimpta, alongside EPKINLY and TIVDAK's contributions, which made up 35% of the total revenue growth. Genmab's operating expenses were approximately DKK 9.9 billion, with 74% directed towards R&D. Total revenue exceeded DKK 15 billion, marking a 29% annual increase, and the net profit reached almost DKK 4 billion. Looking ahead, Genmab anticipates total revenue for 2024 to range from DKK 21.1 billion to DKK 21.7 billion, reflecting a 30% growth at the midpoint, and operating profit is projected between DKK 6.2 billion and DKK 7.1 billion. The company also highlighted strategic decisions to prioritize its Phase 3 programs, including EPKINLY, Rina-S, and acasunlimab, while discontinuing certain early-stage programs to ensure optimal resource allocation.Record Revenue Growth
Total revenue grew by 29% to over DKK 15 billion in the first nine months of 2024. Recurring revenues increased by 37%, driven by strong royalties from DARZALEX, Kesimpta, and other products.
Strong Product Launches
EPKINLY reported 17% growth in the third quarter with $82 million in net sales globally. TIVDAK achieved consistent demand growth with $32 million in sales.
Promising Drug Approvals
EPKINLY received additional approvals, including the first subcutaneous bispecific antibody approved in the EU and the US for certain lymphomas.
Strategic Advancements in Pipeline
Two wholly-owned late-stage assets, Rina-S and acasunlimab, are progressing well in late-stage development, with promising data presented at international conferences.
Profitability and Financial Strength
Operating profit increased by over 27%, reaching more than DKK 4.5 billion. Net profit amounted to almost DKK 4 billion, supported by solid financials and strategic investments.
---
GMAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GMAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $22.75 | $22.33 | -1.85% |
| Aug 08, 2024 | $26.46 | $27.07 | +2.31% |
| May 02, 2024 | $28.75 | $27.72 | -3.58% |
| Feb 14, 2024 | $26.43 | $27.59 | +4.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Genmab A/S (GMAB) report earnings?
Genmab A/S (GMAB) is schdueled to report earning on Feb 12, 2025, TBA Not Confirmed.
What is Genmab A/S (GMAB) earnings time?
Genmab A/S (GMAB) earnings time is at Feb 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GMAB EPS forecast?
GMAB EPS forecast for the fiscal quarter 2024 (Q4) is 0.36.
---